GLP-1 Receptor Agonists and Incretin Therapy
On this page
Direct answer
GLP-1 receptor agonists are incretin mimetics that lower blood glucose in a glucose-dependent way, slow gastric emptying and reduce appetite. Their decisive safety rule is contraindication in a personal or family history of medullary thyroid carcinoma or MEN2, because rodent studies showed thyroid C-cell tumours. Liraglutide, dulaglutide and semaglutide also reduce major cardiovascular events in people with type 2 diabetes at high cardiovascular risk.
What you must remember
- Mechanism: activation of GLP-1 receptors enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and reduces appetite through central action.
- Hypoglycaemia: low intrinsic risk, but the risk rises when combined with insulin or a sulfonylurea, so the partner dose is often reduced.
- Cardiovascular benefit: liraglutide, dulaglutide and semaglutide reduce major adverse cardiovascular events in type 2 diabetes, shown in dedicated outcome trials.
- Weight loss: clinically meaningful weight reduction is a reason for use in obesity, and tirzepatide adds GIP receptor agonism to GLP-1 action.
- Common adverse effects: nausea, vomiting, diarrhoea and early satiety, which are dose-related and often settle with slow titration.
- Serious warnings: acute pancreatitis, gallbladder disease, and rapid HbA1c reduction that can worsen diabetic retinopathy in people with existing retinopathy.
- Contraindications: personal or family history of medullary thyroid carcinoma or MEN2, with caution in severe gastrointestinal disease such as gastroparesis.
Choosing and monitoring an incretin agent
The decision rests on safety screening first and on the clinical goal second. The steps below cover the sequence most often tested and used in practice.
-
Screen for contraindications. Ask about personal or family history of medullary thyroid carcinoma, MEN2 and pancreatitis before any prescription, since these are decisive safety checks.
-
Match the drug to the goal. Liraglutide is given daily, while dulaglutide and injectable semaglutide are given weekly, and all are chosen for glycaemic control with cardiovascular protection. Tirzepatide is considered where greater weight reduction is also a goal.
-
Titrate slowly. Start at the lowest dose and increase in steps, because most gastrointestinal effects are dose-related and are reduced by gradual escalation.
-
Adjust the partner drugs. When combined with insulin or a sulfonylurea, reduce the dose of the partner drug to prevent hypoglycaemia, and recheck glucose frequently during titration.
-
Monitor and counsel. Warn about dehydration from vomiting, which can injure the kidney, teach the symptoms of pancreatitis, and arrange eye review when glucose falls quickly in a patient with retinopathy.
Where the exam tries to catch you
Incretin questions usually test the contraindication, the hypoglycaemia interaction, or the source of the cardiovascular benefit.
- Trap: prescribing a GLP-1 agonist to a patient with a family history of medullary thyroid carcinoma. Correct: this is a contraindication, so the drug is avoided even when the glycaemic need is high.
- Trap: believing incretin drugs cause hypoglycaemia on their own. Correct: their intrinsic risk is low, but hypoglycaemia becomes important when combined with insulin or sulfonylureas.
- Trap: attributing the cardiovascular benefit to glucose lowering alone. Correct: cardiovascular event reduction is shown in outcome trials and is separate from the glucose and weight effects.
Frequently asked questions
Why are GLP-1 receptor agonists contraindicated in medullary thyroid carcinoma?
GLP-1 receptor agonists are contraindicated in a personal or family history of medullary thyroid carcinoma or MEN2 because rodent studies showed thyroid C-cell tumours with these drugs. The human risk is not established, but the precaution is kept in the product labelling. This contraindication is absolute in the labels and is checked before every prescription.
Which GLP-1 receptor agonists reduce major cardiovascular events in type 2 diabetes?
Liraglutide, dulaglutide and semaglutide have shown reductions in major adverse cardiovascular events in people with type 2 diabetes at high cardiovascular risk. These benefits were demonstrated in dedicated outcome trials and were not inferred from glucose lowering alone.
Why does hypoglycaemia risk rise when GLP-1 receptor agonists are combined with insulin?
GLP-1 receptor agonists stimulate insulin release in a glucose-dependent way, so they carry a low intrinsic risk of hypoglycaemia. Combining them with insulin or sulfonylureas adds glucose lowering to drugs that cause hypoglycaemia on their own. The partner drug dose is therefore often reduced.
What adverse effect should prompt urgent review after starting semaglutide?
Severe abdominal pain radiating to the back, with raised serum lipase, should prompt urgent review for acute pancreatitis, and semaglutide is stopped if pancreatitis is suspected. Rapid worsening of diabetic retinopathy after a fast fall in HbA1c is another recognised concern, and any visual change needs prompt ophthalmic review.